| |
Regression coefficient
|
95 % CI
|
P
|
|---|
|
Age, years
|
.036
|
−0.002
|
.010
|
.195
|
|
Male
|
.047
|
−0.023
|
.320
|
.089
|
|
Diabetes
|
.059
|
.014
|
.343
|
.033
|
|
BMI
|
.018
|
−0.024
|
.012
|
.524
|
|
Duration of nephrologist care
|
.013
|
.000
|
.000
|
.655
|
|
Vascular access
|
.151
|
.320
|
.674
|
.000
|
|
Diabetic nephropathy
|
.026
|
−0.112
|
.039
|
.339
|
|
Systolic BP
|
.014
|
−0.004
|
.002
|
.622
|
|
Diastolic BP
|
.048
|
−0.001
|
.011
|
.090
|
|
CTR
|
.157
|
−0.05
|
−0.022
|
.000
|
|
Albumin
|
.176
|
.330
|
.619
|
.000
|
|
Creatinine
|
.162
|
−0.1
|
−0.05
|
.278
|
|
eGFR
|
.187
|
.090
|
.163
|
.000
|
|
Total cholesterol
|
.11
|
.001
|
.005
|
.000
|
|
Triglyceride
|
.074
|
.000
|
.003
|
.013
|
|
HDL-C
|
.040
|
−0.002
|
.009
|
.188
|
|
Calcium
|
.201
|
.223
|
.383
|
.000
|
|
Phosphate
|
.088
|
−0.134
|
−0.032
|
.001
|
|
Ca x P product
|
.020
|
−0.004
|
.008
|
.467
|
|
i-PTH
|
.049
|
−0.001
|
.000
|
.113
|
|
C-reactive protein
|
.002
|
−1.087
|
1.016
|
.948
|
|
Glucose
|
.016
|
−0.001
|
.002
|
.585
|
|
Fe
|
.068
|
.000
|
.005
|
.021
|
|
TIBC
|
.087
|
.001
|
.005
|
.003
|
|
Ferritin
|
.074
|
−0.001
|
.000
|
.013
|
|
ESAa
|
.031
|
−.079
|
.285
|
.268
|
|
Long-acting ESAb
|
.205
|
0.524
|
0.967
|
.000
|
|
Dose of ESA, per 1000 units
|
.075
|
.002
|
.019
|
.015
|
|
ARB/ACE-I
|
.019
|
−0.113
|
.233
|
.497
|
|
Vitamin D
|
.020
|
−0.12
|
0.253
|
.484
|
|
AST-120
|
.017
|
−0.148
|
.275
|
.554
|
|
Iron
|
.000
|
−0.176
|
.176
|
.999
|
-
BMI body mass index, BP blood pressure, CTR cardiothoracic ratio, eGFR estimated glomerular filtration rate, HDL-C high density lipoprotein, i-PTH intact parathyroid hormone, CRP c-reactive protein, TIBC total iron-binding capacity, ESA erythropoiesis-stimulating agents, ARB angiotensin receptor blocker, ACE-I angiotensin-converting enzyme inhibitor
-
aDummy variables was used for usage of any type of ESA (0 for not used, 1 for used)
-
bDummy variables was used for type of ESA (0 for short-acting ESA, 1 for long-acting ESA)
